Patients with hepatitis C genotype 1 through 4 who underwent liver transplantation had significantly high rates of sustained virologic response after treatment with Epclusa for 12 weeks, regardless of cirrhosis status, according to recently published data.
“Among HCV-infected liver transplant recipients, HCV recurrence emerges in nearly all patients,” Kosh Agarwal, MD, from Kings College Hospital, United Kingdom, and colleagues wrote. “Within 5 years posttransplant, cirrhosis related to HCV ensues in approximately 30% of patients with recurrent, chronic HCV infection and is associated with increased graft loss rates and death. In the setting of posttransplant immunosuppression, the rate of hepatic fibrosis is accelerated in HCV-infected patients compared to the pretransplant period.”
The study comprised 79 patients with HCV who underwent treatment with Epclusa (sofosbuvir/velpatasvir [SOF/VEL], Gilead Sciences) posttransplant, including 37 patients with genotype 1, three patients with genotype 2, 35 patients with genotype 3 and four patients with genotype 4.